Scientific work

Prof. Dr. Fahriye Tuğba Köş

109 publications. The source of the information is stated next to each publication.

Back to profile

  1. MEtaStatik pRoStat kaRSinoMlu HaStalaRda SağkalIM analizi vE pRognoStik FaktöRlER; tEk MERkEz dEnEyiMi

    AYBU AVESIS, 2017

    Source: OpenAlex

  2. Evaluation of the effects of red blood cell distribution width on survival in lung cancer patients

    Współczesna Onkologia, 2016

    DOI 10.5114/wo.2016.60072 PMID 27358595 19 citations (Europe PMC) Open-access full textSource: ORCID

  3. Prognostic role of pretreatment platelet/lymphocyte ratio in patients with non-small cell lung cancer

    Wiener Klinische Wochenschrift, 2016

    DOI 10.1007/s00508-015-0724-8 PMID 25720573 28 citations (Europe PMC) Open-access full textSource: ORCID

  4. Böbrek Hücreli Karsinomlu Hastaların Demografik Özellikleri ve Tedavi Sonuçları: Tek Merkez Deneyimi

    Ankara Medical Journal, 2016

    DOI 10.17098/amj.61112 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  5. Duodenal adenocarcinoma: A rare cause of chyloperitoneum (chylous ascites)

    Indian Journal of Cancer, 2015

    DOI 10.4103/0019-509x.175565 PMID 26837993 Source: ORCID

  6. Hypersensitivity and tumor lysis syndrome associated with cetuximab treatment: Should we be afraid?

    Tumori, 2015

    DOI 10.5301/tj.5000246 PMID 25721679 2 citations (Europe PMC) Source: ORCID

  7. 2292 The prognostic significance of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and prognostic nutritional index in metastatic pancreas cancer

    European Journal of Cancer, 2015

    DOI 10.1016/s0959-8049(16)31208-4 1 citation (OpenAlex) Source: OpenAlex

  8. Assessment of Prognostic Value of "Neutrophil to Lymphocyte Ratio" and "Prognostic Nutritional Index" as a Sytemic Inflammatory Marker in Non-small Cell Lung Cancer

    Asian Pacific Journal of Cancer Prevention, 2015

    DOI 10.7314/apjcp.2015.16.9.3997 PMID 25987075 42 citations (Europe PMC) Open-access full textSource: ORCID

  9. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2015

    PMID 26214622 36 citations (Europe PMC) Open-access full textSource: ORCID

  10. Patients with HER2-positive Early Breast Cancer Receiving Adjuvant Trastuzumab: Clinicopathological Features, Efficacy, and Factors Affecting Survival

    Asian Pacific Journal of Cancer Prevention, 2015

    DOI 10.7314/apjcp.2015.16.4.1643 PMID 25743846 2 citations (Europe PMC) Open-access full textSource: ORCID

  11. ASSOCIATION BETWEEN BLOOD UREA NITROGEN/ALBUMIN RATIO AND PROGNOSIS IN NON-SMALL CELL LUNG CANCER

    Acta Medica Mediterranea, 2015

    Source: ORCID

  12. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?

    Journal of B.U.ON., 2015

    Source: ORCID

  13. Comparison of Serum Lipid Levels in Chronic Obstructive Pulmonary Disease and Lung Cancer

    Journal of Clinical and Analytical Medicine, 2015

    DOI 10.4328/jcam.3182 Open-access full textSource: ORCID

  14. Helicobacter Pylori Seropostivity of Colon Cancer

    Journal of Clinical and Analytical Medicine, 2015

    DOI 10.4328/jcam.1826 Source: ORCID

  15. Primary Retroperitoneal Mucinous Cystadenocarcinoma: 5th Male Case in the Literature

    Journal of Clinical and Analytical Medicine, 2015

    DOI 10.4328/jcam.1381 Source: ORCID

  16. Prognostic Factors and Adjuvant Treatments for Surgically Treated Cancers of the Biliary Tract: A Multicentre Study of the Anatolian Society of Medical Oncology (ASMO)

    Asian Pacific Journal of Cancer Prevention, 2014

    DOI 10.7314/apjcp.2014.15.22.9687 PMID 25520089 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  17. Adjuvant chemotherapy outcomes in patients over 65 years with early stage colorectal carcinoma.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2014

    PMID 25536594 Open-access full textSource: ORCID

  18. Adjuvant chemotherapy outcomes in patients over 65 years with early stage colorectal carcinoma

    Journal of B.U.ON., 2014

    Source: ORCID

  19. Evaluation of the effect of comorbidity on survival in pancreatic cancer by using "Charlson Comorbidity Index" and "Cumulative Illness Rating Scale"

    Wiener Klinische Wochenschrift, 2014

    DOI 10.1007/s00508-013-0453-9 PMID 24249323 12 citations (Europe PMC) Source: ORCID

  20. Serum 25-hydroxy Vitamin D Status is Not Related to Osteopenia/Osteoporosis Risk in Colorectal Cancer Survivors

    Asian Pacific Journal of Cancer Prevention, 2014

    DOI 10.7314/apjcp.2014.15.8.3377 PMID 24870725 1 citation (Europe PMC) Open-access full textSource: ORCID

  21. Treatment and Outcomes of Ewing Sarcoma in Turkish Adults: A Single Centre Experience

    Asian Pacific Journal of Cancer Prevention, 2014

    DOI 10.7314/apjcp.2014.15.1.327 PMID 24528050 10 citations (Europe PMC) Open-access full textSource: ORCID

  22. Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: Retrospective analysis of 667 patients anatolian society of medical oncology

    Oncology (Switzerland), 2013

    DOI 10.1159/000336902 PMID 23392240 14 citations (Europe PMC) Open-access full textSource: ORCID

  23. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2013

    PMID 24065471 6 citations (Europe PMC) Source: ORCID

  24. Administration of contrast media just before cisplatin-based chemotherapy increases cisplatin-induced nephrotoxicity.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2013

    PMID 23613416 11 citations (Europe PMC) Source: ORCID

  25. Administration of contrast media just before cisplatin-based chemotherapy increases cisplatin-induced nephrotoxicity

    Journal of B.U.ON., 2013

    Source: ORCID

  26. DEMOGRAPHIC FEATURES AND FACTORS AFFECTING OVERALL SURVIVAL IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: A RETROSPECTIVE ANALYSIS IN TURKEY

    Acta Medica Mediterranea, 2013

    Source: ORCID

  27. Evaluation of Renal Function Using the Level of Neutrophil Gelatinase-Associated Lipocalin is Not Predictive of Nephrotoxicity Associated with Cisplatin-Based Chemotherapy

    Asian Pacific Journal of Cancer Prevention, 2013

    DOI 10.7314/apjcp.2013.14.2.1111 PMID 23621196 5 citations (Europe PMC) Open-access full textSource: ORCID

  28. Evaluation of the Renal Function Using Cystatin C Level in the Patients Receiving Cisplatin-Based Chemotherapy

    Renal Failure, 2013

    DOI 10.3109/0886022x.2013.777929 PMID 23530579 11 citations (Europe PMC) Open-access full textSource: ORCID

  29. Evaluation of vitamin D status and risk factors of osteopenia/osteoporosis in colorectal cancer survivors

    European Journal of Cancer, 2013

    Source: ORCID

  30. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes

    Journal of B.U.ON., 2013

    Source: ORCID

  31. Pages 46-48

    Kırıkkale University Institutional Repository, 2013

    DOI 10.24938/kutfd.124757 Open-access full textSource: OpenAlex

  32. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study.

    PubMed, 2012

    PMID 22517701 16 citations (Europe PMC) Open-access full textSource: OpenAlex

  33. Gemcitabine Alone versus combination of Gemcitabine and Cisplatin for the Treatment of Patients with Locally Advanced and/or Metastatic Pancreatic Carcinoma: A Retrospective Analysis of multicenter study (Anatolian Society of Medical Oncology)

    Neoplasma, 2012

    DOI 10.4149/neo_2012_038 PMID 22329849 12 citations (Europe PMC) Open-access full textSource: OpenAlex

  34. Isolated testicular metastasis of gastric cancer

    Journal of Gastrointestinal Cancer, 2012

    DOI 10.1007/s12029-011-9305-x PMID 21761128 2 citations (Europe PMC) Source: ORCID

  35. Multiple primary malignant neoplasms: multi-center results from Turkey.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2012

    PMID 23335539 21 citations (Europe PMC) Source: ORCID

  36. Administration of contrast media just before the cisplatin-based chemotherapy increases the cisplatin-induced nephrotoxicity

    Journal of Clinical Oncology, 2012

    DOI 10.1200/jco.2012.30.15_suppl.e13031 12 citations (OpenAlex) Source: ORCID

  37. Is There an Association between Blood Group and Survival in Pancreatic Cancer?

    Asian Pacific Journal of Cancer Prevention, 2012

    DOI 10.7314/apjcp.2012.13.12.6151 PMID 23464421 7 citations (Europe PMC) Open-access full textSource: ORCID

  38. Long Term Survivors with Metastatic Pancreatic Cancer Treated with Gemcitabine Alone or Plus Cisplatin: a Retrospective Analysis of an Anatolian Society of Medical Oncology Multicenter Study

    Asian Pacific Journal of Cancer Prevention, 2012

    DOI 10.7314/apjcp.2012.13.5.1841 PMID 22901133 8 citations (Europe PMC) Open-access full textSource: ORCID

  39. Multiple primary malignant neoplasms: Multi-center results from Turkey

    Journal of B.U.ON., 2012

    Source: ORCID

  40. Primary anorectal malignant melanoma: rare but highly lethal malignancy

    Turkish Journal of Medical Sciences, 2012

    DOI 10.3906/sag-1202-62 2 citations (OpenAlex) Open-access full textSource: ORCID

  41. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study

    Journal of B.U.ON., 2012

    Source: ORCID

  42. Adjuvant therapy for gallbladder and bile duct cancers: retrospective comparative study.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2011

    PMID 22006751 2 citations (Europe PMC) Source: ORCID

  43. Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2011

    PMID 22006750 4 citations (Europe PMC) Source: ORCID

  44. Long term survival in a metastatic alveolar soft part sarcoma at the time of diagnosis: a case with 17 years of follow-up.

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2011

    PMID 21766518 2 citations (Europe PMC) Source: ORCID

  45. ADJUVANT THERAPY FOR GALL BLADDER AND BILE DUCT CANCERS: RETROSPECTIVE COMPARATIVE STUDY

    Annals of Oncology, 2011

    Source: ORCID

  46. Adjuvant therapy for gallbladder and bile duct cancers: retrospective comparative study

    Journal of B.U.ON., 2011

    Source: ORCID

  47. Comparison of Cisplatin-5-Fluorouracil-Folinic Acid versus Modified Docetaxel-Cisplatin-5-Fluorouracil Regimens in the First-Line Treatment of Metastatic Gastric Cancer

    Chemotherapy, 2011

    DOI 10.1159/000327840 PMID 21597287 14 citations (Europe PMC) Source: ORCID

  48. Gemcitabine and cisplatin in patients with carcinoma of unknown primary site

    Medical Oncology, 2011

    DOI 10.1007/s12032-010-9465-8 PMID 20300978 Source: ORCID

  49. HELICOBACTER PYLORI SEROPOSITIVITY IN COLORECTAL CANCER PATIENTS

    Annals of Oncology, 2011

    Source: ORCID

  50. Long term survival in a metastatic alveolar soft part sarcoma at the time of diagnosis: a case with 17 years of follow-up

    Journal of B.U.ON., 2011

    Source: ORCID